{"page":{"totalFilteredElements":68},"studies":[{"active":true,"description":"Klinische Pr&#252;fung der Phase III von CPX-351 zur Behandlung von Kindern mit Myeloischer Leuk&#228;mie mit Down-Syndrom 2018","eudractNumber":"2018-002988-25","id":8960,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-02-22T12:45:46+01:00","shortTitle":"ML-DS 2018","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A prospective randomized, double-blind, placebo-controlled, multi-center phase III study to evaluate the efficacy and safety of mocravimod as an adjunctive and maintenance treatment in adult acute myeloid leukemia (AML) patients undergoing allogeneic hematopoietic cell transplantation (HCT)","eudractNumber":"2021-002864-36","id":10399,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":"NCT05429632","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-05-25T12:31:16+02:00","shortTitle":"MOTRANS - PKRPC001","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation","eudractNumber":"2021-002531-27","id":10386,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05243797","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-08-29T11:17:17+02:00","shortTitle":"MajesTEC-4","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC \nand Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and \nLenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in \nParticipants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended \nfor Autologous Stem Cell Transplant as Initial Therapy&#160;","eudractNumber":"2022-000909-28","id":9487,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05552222","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-06-01T12:08:16+02:00","shortTitle":"MajesTEC-7, 64007957MMY3005","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma","eudractNumber":"2023-505436-35-00","id":11544,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-12-01T10:14:00+01:00","shortTitle":"MorningLyte","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Improvement of functional outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q &#8211; IMPROVE CODEL: the NOA-18 trial","eudractNumber":"2018-005027-16","id":6809,"indications":[{"id":"zns","name":"Hirntumore (ZNS Tumore)"},{"id":"zns1","name":"Astrozytäre Gliome (Astrozytom, Glioblastom)"},{"id":"zns2","name":"Meningeom"},{"id":"zns3","name":"Akustikusneurinom (Vestibularis-Schwannom)"},{"id":"zns4","name":"Weitere Hirntumoren"}],"mutations":[{"name":"1p/19q-Kodeletion","id":"mt_261"}],"nctNumber":"NCT05331521","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-06-17T12:27:00+02:00","shortTitle":"NOA-18 / IMPROVE CODEL: the NOA-18 trial","therapeutical":true,"therapyLines":[{"id":"tl_6","name":"Adjuvant"}]},{"active":true,"description":"Preoperative radiotherapy versus postoperative radiotherapy after neoadjuuvant chemotherapy (\"NeoRad\") in high-risk breast cancer: a prospective, randomized, international, multicenter Phase III trial","eudractNumber":null,"id":10183,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT04261244","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-07-02T08:46:14+02:00","shortTitle":"NeoRad","therapeutical":true,"therapyLines":[{"id":"tl_7","name":"Neoadjuvant"}]},{"active":true,"description":"A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma","eudractNumber":"2024-513317-12-00","id":9932,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-30T09:54:54+02:00","shortTitle":"PRISM-1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>Pre-Operative Treatment in rEseCTable cOlon canceR</div><div>(PROTECTOR/FIRE-10; AIO KRK0620; IAG-VO-0323)</div><div>Prospective, randomized, open, multicenter Phase III trial</div><div>to investigate the efficacy preoperative systemic therapy in</div><div>advanced colon cancer</div>","eudractNumber":"2023-508076-11-00","id":11330,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-01T08:30:33+02:00","shortTitle":"PROTECTOR/ Fire-10","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR&#8217;S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)</div>","eudractNumber":"2022-502660-20","id":9250,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT06091254","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-10T09:10:35+01:00","shortTitle":"R1979-HM-2298 (OLYMPIA-1)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}